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Erythroid terminal differentiation entails cell divisions that are coupled to progressive decreases in cell 
size. EpoR signaling is essential for the survival of erythroid precursors, but it is unclear whether it has 
other functions in these cells. Here we endowed mouse precursors that lack the EpoR with survival 
signaling, finding that this was sufficient to support their differentiation into enucleated red cells, but that 
the process was abnormal. Precursors underwent fewer and slower cell cycles and yet differentiated 
into smaller red cells. Surprisingly, EpoR further accelerated cycling of early erythroblasts, the fastest 
cycling cells in the bone marrow, while simultaneously increasing their cell size. EpoR-mediated 
formation of larger red cells was independent of the established pathway regulating red cell size by iron 
through Heme-regulated eIF2α kinase (HRI). We confirmed the effect of Epo on red cell size in human 
volunteers, whose mean corpuscular volume (MCV) increased following Epo administration. This 
increase persisted after Epo declined and was not the result of increased reticulocytes. Our work 
reveals a unique effect of EpoR signaling on the interaction between the cell cycle and cell growth. 
Further, it suggests new diagnostic interpretations for increased red cell volume, as reflecting high Epo 
and erythropoietic stress. 
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Introduction 
 
Red cell formation (erythropoiesis) is continuous throughout life, replenishing senescent red cells. Red 
cell production rate is accelerated up to ten fold in the erythropoietic stress response, meeting 
increased demand in anemia, bleeding or hypoxic stress. Indeed, anemia is a common manifestation of 
nutritional deficiencies, malaria, chronic disease, cancer or hereditary hemoglobinopathies, accounting 
for 8.8% of all disability globally in 2010, with the highest burden afflicting women and children under 
five 1.  Erythropoietin (Epo) is the principal and essential regulator of erythropoietic rate in both the 
basal state and in the response to stress. Epo acts through its receptor, EpoR, a transmembrane type I 
cytokine receptor 2. EpoR is first expressed in the earliest erythroid-committed progenitors and peaks in 
colony-forming-unit-erythroid (CFU-e) progenitors, a stage that undergoes amplification cell divisions 3-6 
(Extended Data Fig 1). EpoR becomes essential, however, only with the onset of erythroid terminal 
differentiation (ETD) 7, a process that starts at the end of the CFU-e stage with the sharp induction of 
erythroid gene transcription 6. During ETD, erythroblasts undergo 3 to 5 maturational cell divisions in 
which they become smaller, express hemoglobin and ultimately enucleate to form reticulocytes. The 
latter lose intracellular organelles and mature into biconcave red cells.   
 
The essential function of EpoR is exerted early in ETD.  It rescues late CFU-e, proerythroblasts and 
basophilic erythroblasts (here collectively termed ‘early erythroblasts’) from apoptosis 8,9, a principal 
mechanism of erythropoietic rate regulation 10,11. EpoR expression is downregulated in late 
erythroblasts, which no longer depend on EpoR signaling for survival 4,12,13 (Extended Data Fig 1). 
Epo-/- or Epor-/- mice die on embryonic day 13 (E13) as a result of severe anemia 7,14,15. Their fetal 
livers, the site of hematopoiesis at mid-gestation, contain early erythroid progenitors including CFU-e, 
but are entirely devoid of cells undergoing ETD 7,14,15. 
 
The absolute dependence of early erythroblasts on EpoR signaling for survival makes it challenging to 
identify other essential functions of EpoR in these cells. Key open questions include a role for EpoR in 
cell cycle regulation. Although early reports suggested that Epo does not alter the erythroblast cell cycle 
16, EpoR signaling induces some cell cycle genes in these cells 17, and is essential for the cycling of 
Epo-dependent cell lines 18,19 and of CFU-e in culture 20. EpoR also promotes cycling in yolk-sac -
derived primitive erythroblasts during early embryonic development 21. These findings raise the 
possibility that EpoR may be required for the cycling of adult-type erythroblasts and that this function 
may contribute to the erythropoietic stress response.  
 
A second open question is whether EpoR is required for induction of erythroid genes. EpoR and similar 
cytokine receptors do not instruct lineage choice and are instead required for essential permissive 
functions 22-25. It is not clear, however, whether these include signals that facilitate erythroid gene 
transcription. EpoR signaling was shown to phosphorylate GATA1, a key erythroid transcriptional 
regulator, but the broad impact of this on GATA1 function is not clear 26.  
 
To address these gaps, we developed a genetic system that allowed us to examine essential non-
survival functions of EpoR signaling in erythroid differentiation. We rescued mouse Epor-/- fetal liver 
erythroid progenitors from apoptosis by transduction with the anti-apoptotic protein bcl-xL, and 
compared their ensuing differentiation with that of Epor-/- progenitors that were rescued by re-
introduction of the EpoR. We found that the bcl-xL survival signal, in the absence of any EpoR 
signaling, was sufficient to allow expression of the erythroid transcriptional program and formation of 
enucleated red cells. However, key ETD features were abnormal. First, erythroblasts underwent slower 
and fewer cell cycles, generating far fewer red cells, showing that EpoR is essential for the rapid cycling 
of early erythroblasts.  We confirmed this using a mouse transgenic for a fluorescent reporter of cell 
cycle length, finding that Epo stimulation shortened cell cycle length in vivo in early erythroblasts, cells 
that are already amongst the fastest cycling cells in the bone marrow 27,28. Second, we found that, 
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted December 1, 2020. ; https://doi.org/10.1101/2020.11.30.404780doi: bioRxiv preprint 
unexpectedly, despite its stimulation of rapid erythroblast cycling, EpoR signaling increases cell size in 
both erythroblasts and red cells. This contrasts with the well -established reverse relationship between 
the number of cell divisions in ETD and red cell size 29-32. Using mice doubly deleted for both EpoR and 
HRI, we found that EpoR regulation of red cell size is also independent of the well described iron and 
heme-regulated pathway 33-35. We confirmed these findings in healthy human volunteers that were 
administered Epo, finding an increased MCV that persisted long after Epo and reticulocyte levels 
returned to baseline. Our work reveals novel functions for the EpoR, including its likely modulation of 
red cell size during hypoxia, anemia and other high-Epo erythroid stress syndromes. These 
mechanistic insights will aid diagnostic interpretation of red cell size abnormalities commonly found in 





Non-survival EpoR signals are essential for normal erythroid differentiation 
 
Erythroid differentiation in the Epor-/- fetal liver is arrested at the CFU-e stage, which leads to the death 
of the Epor-/- embryo on embryonic day 13 (E13) 7,14,15,21. Epor-/- fetal liver CFU-e can be rescued in vitro 
by transduction with EpoR or a similar cytokine receptor 7,23.  Here we asked whether transducing Epor-
/- CFU-e with bcl-xL, an anti-apoptotic transcriptional target of EpoR signaling 36-39, would be sufficient to 
support erythroid differentiation. As control, we transduced Epor-/- cells from the same fetal livers with 
the EpoR. The use of bicistronic retroviral expression vectors allowed us to track transduced cells (Fig 
1a).  
 
We plated the transduced cells in methylcellulose semi-solid medium and examined their ability to give 
rise to CFU-e colonies (Fig 1b). As expected, Epor-/- cells transduced with empty vector failed to give 
rise to any colonies, whereas EpoR-transduced Epor-/- cells (EpoR- Epor-/-) generated CFU-e colonies 
in an Epo-dependent manner. Bcl-xL-transduced Epor-/- cells (Bcl-xL- Epor-/-) failed to give rise to CFU-e 
colonies of the usual size and appearance (Fig 1b). Close inspection showed, however, that they 
generated a similar number of much smaller cell clusters, which were not scored as CFU-e colonies in 
Figure 1b. These smaller clusters contained fewer than16 hemoglobinized cells, compared with 16 to 
32 cells in EpoR-supported CFU-e colonies (Fig 1c). The area occupied by Bcl-xL- Epor-/- colonies was 
approximately half that of EpoR- Epor-/- CFU-e colonies (439 ± 208 µm2 versus 217 ± 106 µm2, mean ± 
SD for EpoR- Epor-/- v. Bcl-xL- Epor-/-, respectively; n = 75 colonies for each genotype;  p = 3.6 x 10-13, 
Fig 1d), suggesting approximately 3-fold difference in colony volume due to fewer and smaller cells 
(see below). Co-transduction of Epor-/- cells with both Bcl-xL and a constitutively active form of Stat5, a 
transcription factor activated by EpoR signaling, was also not sufficient to support the formation of 
normally- sized Epor-/- CFU-e colonies (Fig 1b).  
 
Liquid cultures of both Bcl-xL- Epor-/- with and without Epo and EpoR- Epor-/- erythroblasts with Epo 
contained hemoglobinized cells by 36 hours post-transduction, while EpoR- Epor-/- erythroblasts without 
Epo did not (Fig 1e). However, differentiation of Bcl-xL- Epor-/- erythroblasts appeared to be 
accelerated, with cultures containing smaller and morphologically more mature erythroblasts including 
many fully differentiated and enucleated cells; there were few if any enucleated cells in EpoR- Epor-/- 
erythroblasts cultured with Epo at this time (Fig 1e).  
 
Differentiation abnormalities of Bcl-xL- Epor-/- erythroblasts were also evident from flow cytometric 
analysis. The earliest progenitors express only low or medium levels of CD71, encoded by the 
transferrin receptor (Tfrc).  In wild-type progenitors, the transition from the CFU-e stage to ETD is 
marked by sharp upregulation of CD71, followed by the upregulation of Ter119, a marker specific for 
ETD erythroblasts and red cells 6,27,40. We previously found that freshly explanted Epor-/-  fetal livers lack 
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CD71high cells, and do not express Ter119, reflecting their developmental arrest at the onset of ETD 
(the small number of Ter119+ cells in the Epor-/- fetal liver are transient yolk-sac-derived primitive 
erythroblasts 40, Fig 1f). Here we found that transduction of Epor-/- fetal liver cells with EpoR allowed 
them to resume the expected sequence of cell surface marker expression, with rapid upregulation of 
CD71 by 18 hours post infection, followed by the upregulation of Ter119 by 36 hours (Fig 1g). By 
contrast, Bcl-xL- Epor-/- cells failed to upregulate CD71 at any point of the culture although they did 
upregulate Ter119 (Fig 1g). 
 
Thus, our initial analysis showed that, when rescued from apoptosis by Bcl-xL, Epor-/- progenitors can 
differentiate into hemoglobinized, enucleated red cells in the absence of additional EpoR signals. 
However, the ETD they undergo has a number of abnormalities.  Bcl-xL- Epor-/- erythroblasts failed to 
upregulate CD71, and their differentiation appeared to be accelerated, generating fewer and smaller 
red cells.  
 
Erythroblasts undergo fewer and slower cell cycles in the absence of EpoR signaling 
 
CFU-e express the receptor tyrosine kinase Kit and the Interleukin-3 (IL3) receptor, both of which 
increase CFU-e number 23,41,42. The addition of stem cell factor (SCF, the Kit ligand) and IL3 to the 
media increased the overall yield of transduced Epor-/- fetal liver cells, but the difference in cell number 
between Bcl-xL- Epor-/- and EpoR- Epor-/- erythroblasts remained (Extended Data Fig 2a). We modified 
our transduction protocol to make use of this improvement in yield, culturing freshly transduced Epor-/- 
progenitors for 15 hours in SCF and IL3 before transitioning the cells to an Epo -containing medium for 
the remainder of differentiation. Since SCF and IL3 also promote the growth of myeloid cells, all 
subsequent analysis was performed on cells that were both negative for non-erythroid lineage markers 
and positive reporters of transduction (hCD4 and/or GFP, Extended Data Fig 2b, Fig 2a).  
 
Pre-incubation with SCF and IL3 did not ameliorate the abnormalities of Bcl-xL- Epor-/- erythroblast 
differentiation. In particular, these cells failed to upregulate CD71 throughout differentiation (Fig 2a, b). 
We examined the possibility that these abnormalities were the result of over-expression of Bcl-xL, rather 
than the absence of EpoR signaling, by including an additional control in which Epor-/- progenitors were 
co-transduced with both EpoR and Bcl-xL, each linked to a distinct reporter (Extended Data Fig 2c). 
These doubly-transduced progenitors were indistinguishable from cells transduced with only the EpoR, 
indicating that the lower cell number of Bcl-xL- Epor-/- erythroblasts and their failure to upregulate CD71 
were not the result of Bcl-xL over-expression, but rather, of absent EpoR signaling (Extended Data Fig 
2d-g).  
 
CD71 is the transferrin receptor, critical for importing iron-bound transferrin into erythroid cells for heme 
synthesis. Iron deficiency leads to microcytic anemia. We therefore examined whether iron deficiency 
might account for the abnormal differentiation of Bcl-xL- Epor-/- erythroblasts, by co-transducing Epor-/- 
progenitors with Tfrc, in addition to either Bcl-xL or EpoR (Fig 2c- e). As an alternative approach, we 
added iron-loaded ferric-salicylaldehyde isonicotinoyl hydrazone (Fe- SIH) to the culture medium of 
both Bcl-xL- Epor-/- and EpoR- Epor-/- erythroblasts. SIH is a cell-membrane- permeable synthetic iron 
chelate, which, when pre-loaded with iron, will deliver iron intracellularly for heme synthesis, bypassing 
defects in Tfrc iron transport in erythroid cells 43. Neither of these approaches altered the proliferative 
defect of Bcl-xL- Epor-/- erythroblasts (Fig 2c, e). The viability of all erythroblasts was high with no 
significant difference between Bcl-xL- Epor-/- and EpoR- Epor-/- erythroblasts (Fig 2d), suggesting that 
the proliferative deficit of Bcl-xL- Epor-/- erythroblasts is the result of fewer cell divisions. In the first 26 
hours of culture, the difference in growth rate for the Bcl-xL- Epor-/- and EpoR- Epor-/- cultures indicated 
a substantial difference in doubling time, of 6.1 h for EpoR- Epor-/- erythroblasts, compared with 8.6 h 
for Bcl-xL- Epor-/-  erythroblasts (95% confidence intervals: 5.6 to 7.1 h and 7.7 to 10.4 h, respectively; 
Fig 2c, e). A cycle length of 6 hours for EpoR- Epor-/- is in good agreement with our recent direct 
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measurement of a 6 hour cell cycle duration in early erythroblasts in vivo 27, and with an independent 
measurement using a fluorescent timer protein that found early erythroblasts to have the shortest cell 
cycle amongst bone marrow hematopoietic progenitors 28. 
 
In addition to its role in heme synthesis, iron has multiple cellular functions, including its requirement in 
ribonucleotide reductase (RNR) catalysis of deoxyribonucleotide synthesis. Depletion of the intracellular 
iron pool can therefore lead to inhibition of both DNA synthesis and cell growth 44. We supplemented 
the culture medium with deoxyribonucleosides (dN), which bypass RNR via the deoxyribonucleoside 
kinase salvage pathway 45. This too had little effect on the proliferative defect of Bcl-xL- Epor-/- 
erythroblasts (Fig 2c, e). Taken together, in the absence of EpoR signaling, erythroblasts fail to 
upregulate CD71 and also undergo fewer and longer cell divisions. The rescue of intracellular iron or 
the exogenous supply of deoxyribonucleosides does not rescue these deficits.   
 
Epo administration shortens cell cycle duration in early erythroblasts in vivo 
 
To test whether EpoR stimulation altered cell cycle length in vivo, we used a recently -engineered 
mouse expressing a live-cell fluorescent reporter of cell cycle speed 28. Specifically, the mouse 
expresses a transgene encoding histone H2B fused to a fluorescent timer protein (H2B-FT, Fig 2f).  
H2B-FT fluoresces blue when first synthesized but matures over 1 -2 hours into a red fluorescent 
protein. Due to its short half-life, the level of blue fluorescent H2B-FT in the cell is minimally affected by 
cell cycle length. In contrast, the red-fluorescent H2B-FT accumulates to higher levels in cells of long 
cycles due to its extensive stability. The ratio of blue to red fluorescence was found to be a sensitive 
indicator of cell cycle length in vivo in diverse cell types including bone marrow progenitors 28.  
 
We injected H2B-FT transgenic mice with either Epo (100 U) or saline once daily for 2 days, and 
analyzed bone marrow at 48 h. We found a clear shift in the blue to red fluorescence ratio, indicating 
significant cell cycle shortening, in all bone marrow early erythroblast subsets in Epo injected mice (Fig 
2f, g and Extended Data Fig 3). These data are consistent with our results in the fetal liver (Fig 2c, e), 
together indicating that Epo stimulation increases cell cycle speed in early erythroblasts.  
 
Slower S phase in the absence of EpoR signaling, partially rescued by iron supplementation 
 
We recently found that the onset of ETD in the fetal liver is closely linked to cell cycle remodeling 
events that radically shorten the cell cycle, from an average of 15 hours in BFU-e and CFU-e, to 6 
hours in early erythroblasts 6,27,40. The short 6 hour cycle includes a shortened S phase, lasting only 4 
hours 27. Our findings here show that EpoR signaling is required for the short cycle of early 
erythroblasts (Fig 2e, g) and led us to ask whether EpoR was required for the shortening only of G1, or 
whether it also played a role in S phase shortening. The shortening of G1 by cytokine receptor signaling 
is well documented 46-50. However, to our knowledge, there are no reports of cytokine or growth factor 
signaling altering the speed and duration of S phase.  
 
To examine this, we pulsed cultures of EpoR- Epor-/- and Bcl-xL- Epor-/- erythroblasts with 
bromodeoxyuridine (BrdU), a nucleoside analog that is incorporated into DNA during S phase, and 
analyzed the cells 30 min following the pulse. The fraction of cells that are labeled with an anti-BrdU 
antibody indicates the proportion of cells in S phase at the time of the pulse. Further, the amount of 
BrdU incorporated into S phase cells during the 30 minutes pulse, as measured by the BrdU mean 
fluorescence intensity (MFI) of S phase cells, indicates the intra-S phase rate of DNA synthesis, which 
is inversely related to S phase duration 27. We found that, in the first 10 hours of ETD, BrdU MFI in S 
phase cells was 50% higher in EpoR- Epor-/-, compared with Bcl-xL- Epor-/- erythroblasts, suggesting 
that EpoR signaling increases intra-S phase DNA synthesis rate and shortens S phase duration by 50% 
(Fig 3a, b).  
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If the slowing of S phase alone could account for the increased cell cycle length of Bcl-xL- Epor-/- 
erythroblasts, S phase would constitute a larger fraction of the total cell cycle duration. However, the 
fraction of Bcl-xL- Epor-/- erythroblasts in S phase was actually somewhat lower, with a corresponding 
increase in the fraction of cells in G1 (Fig 3b), and little change in the fraction of cells in G2 or M (not 
shown). These observations suggest that, in the absence of EpoR signaling, both S and G1 phases 
lengthen. 
 
We examined the potential roles of iron and nucleotides in the slower S phase of Bcl-xL- Epor-/- 
erythroblasts.  Supplementing the culture medium with Fe-SIH increased S phase speed modestly in 
both Bcl-xL- Epor-/- and EpoR- Epor-/- erythroblasts (Fig 3c). Across 4 experiments, the increase in S 
phase speed in Bcl-xL- Epor-/- erythroblasts was statistically significant but accounted for only 10% of 
the difference between Bcl-xL- Epor-/- and EpoR- Epor-/-  erythroblasts (relative S phase speed of 0.68 ± 
0.07 for  Bcl-xL- Epor-/- , 1.2 ± 0.3  for EpoR- Epor-/-, and 0.75 ± 0.07 for  Bcl-xL- Epor-/- supplemented 
with Fe-SIH, Fig 3d). There was no rescue of S phase speed in Bcl-xL- Epor-/- erythroblasts by either 
the addition of deoxyribonucleosides nor double transduction with both Bcl-xL and Tfrc (Fig 3d), 
although there was a small increase in the number of cells in S phase in the latter (Fig 3e). Taken 
together, these results indicate that EpoR is essential for accelerating both G1 and S phases of the 
shortened cell cycles in early ETD, largely, but not exclusively, via mechanisms independent of iron and 
the nucleotide pool.  
 
Premature induction of the CDK inhibitor p27KIP1 in the absence of EpoR signaling 
 
We compared gene expression in EpoR- Epor-/- and Bcl-xL- Epor-/- erythroblasts during the 48-hour 
differentiation time course, using RT-qPCR (Extended Data Fig 4). ETD markers Slc4a1 (Band3) and 
Hbb1 were induced similarly in both cell types. There were no significant differences in the expression 
of transcription factors, with the possible exception of Tal1, whose levels were 30% lower in Bcl-xL- 
Epor-/- (p<0.005, Extended Data Fig 4).  
 
Among cell cycle regulators, we found few differences. The clear exception was the CDK inhibitor 
p27KIP1 (encoded by Cdkn1b), previously shown to be induced towards the end of ETD, as part of the 
mechanism that slows the cycle and leads to mitotic exit prior to enucleation 51-54. Here we found that 
p27KIP1 was induced prematurely in Bcl-xL- Epor-/- compared with EpoR- Epor-/- cells, with levels 2.3 and 
2.6 -fold higher at 19 and 24 hours of culture (p<0.005, Extended Data Fig 4). The premature induction 
of p27KIP1 might explain the slower and fewer cycles of Bcl-xL- Epor-/- cells (Fig 2, 3), and may also 
contribute to the accelerated maturation of Bcl-xL- Epor-/- erythroblasts (Fig 1e and further analysis 
below). We also found a small but significant expression difference in a second member of the CIP/KIP 
family, p57KIP2 (encoded by Cdkn1c).  p57KIP2 is expressed in CFU-e cells, and undergoes rapid 
downregulation at the onset of ETD, precipitating the concurrent shortening of the cycle 27. Here we 
found that, in the absence of EpoR, p57KIP2 downregulation at the onset of ETD was largely intact. 
These findings indicate that p57KIP2 downregulation and EpoR signaling each drive cell cycle shortening 
in early ETD by largely independent mechanisms.  
 
Imaging flow cytometry shows Epor-/- erythroblasts and reticulocytes are smaller 
 
Erythroid maturational cell divisions are coupled to loss in cell size. This is supported by the findings 
that drugs, nutritional deficiencies or genetic perturbations that reduce the number of cell divisions lead 
to the formation of larger red cells (macrocytosis 29-32,55). Therefore, we expected that the fewer cell 
divisions of Bcl-xL- Epor-/- erythroblasts would result in larger size for these cells. Instead, they 
appeared to be smaller (Fig 1e).  To address this question quantitatively, we measured cell and nuclear 
size in several thousand EpoR- Epor-/- and Bcl-xL- Epor-/- erythroblasts by imaging flow cytometry, at 20 
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and 46 hours of differentiation (Fig 4a, b). We calibrated the measured cell areas by comparing them 
with those of beads of known diameter (Extended Data Fig 5a). We found that both cell and nuclear 
size were significantly smaller in Bcl-xL- Epor-/- erythroblasts, at both time points (at t= 46 h, cell 
diameter was 7.5 ± 0.6 µm and 6.7 ± 0.7 µm for EpoR- Epor-/- and Bcl-xL- Epor-/- erythroblasts, 
respectively, mean ± sem, p = 0.001). Although Bcl-xL- Epor-/- erythroblasts express significantly lower 
CD71 (Fig 2a, b), the addition of Fe-SIH to the culture did not alter their smaller cell or nuclear size (Fig 
4b). 
 
We asked whether the smaller size of Bcl-xL- Epor-/- erythroblasts could reflect an accelerated process 
of differentiation. If at any given time of the culture Bcl-xL- Epor-/- erythroblasts were smaller only as a 
result of being at a more advanced maturation stage, they should give rise to normally- sized 
enucleated reticulocytes, albeit at an earlier time. However, imaging flow-cytometry showed that Bcl-xL- 
Epor-/- reticulocytes were significantly smaller (5.6 ± 0.5 µm vs. 4.5 ± 0.15 µm for respective diameters 
of EpoR- Epor-/-  vs. Bcl-xL- Epor-/- reticulocytes, mean ± sem, p = 0.002, Fig 4c, d).  
 
It remained possible that the smaller size of Bcl-xL- Epor-/- erythroblasts and reticulocytes is the result of 
over-expression of Bcl-xL, rather than absent EpoR signaling. To address this, we doubly transduced 
Epor-/- fetal liver cells with both EpoR and Bcl-xL. We used the the Bcl-xL-linked GFP and the EpoR-
linked hCD4 fluorescence reporters to quantify expression and ensured that all comparisons were 
made between cells expressing similar levels of each retroviral vector (Extended Data Fig 5b-d). We 
found that erythroblasts and reticulocytes transduced with both EpoR and Bcl-xL were similar in size to 
those transduced with only the EpoR, and significantly larger than those transduced with only Bcl-xL 
(Fig 4e; Extended Data Fig 5c, d). Therefore, Bcl-xL over-expression is not the cause of the smaller 
size of Bcl-xL- Epor-/- erythroblasts and reticulocytes. Taken together, these observations suggested a 
dependence of erythroblast and reticulocyte size on EpoR signaling, that appeared to be independent 
of iron.  
 
EpoR regulation of red cell size is independent of HRI 
 
In addition to the number of maturational cell divisions, red cell size is regulated by iron status. HRI is 
activated by heme deficiency and mediates the formation of smaller, hypochromic red cells 56. It 
phosphorylates eukaryotic initiation factor 2a (eIF2a), inhibiting translation of globins and most other 
cellular transcripts. Our results showed that Bcl-xL- Epor-/- erythroblasts and reticulocytes were smaller 
and failed to upregulate CD71 (Tfrc), the principal iron transporter. Although iron supplementation did 
not appear to rescue the smaller size of Bcl-xL- Epor-/- erythroblasts (Fig 4b), it remained possible that 
intracellular iron delivery was somehow incomplete.   
 
To determine definitively the relevance of the iron/heme/HRI pathway to the smaller size of Bcl-xL- 
Epor-/- erythroblasts, we generated mice that were doubly deleted for both Epor and Hri (Fig 5a). The 
Epor-/-Hri-/- mice were phenotypically similar to Epor-/- mice, dying at mid-gestation as a result of severe 
anemia. We rescued both singly (Epor-/-) and doubly- deleted (Epor-/-Hri-/-) fetal liver cells in parallel, by 
transduction with either Bcl-xL or EpoR (Fig 5b-e). Bcl-xL- transduced erythroblasts were indeed larger 
on the Epor-/-Hri-/- genetic background than on the Epor-/- background. However, EpoR-transduced 
erythroblasts were also larger on the Epor-/-Hri-/- background, compared with the Epor-/- background. 
Further, for a given genetic background, either Epor-/-Hri-/- or Epor-/-, the difference in size between Bcl-
xL and EpoR-rescued cells remained (Fig 5b-e). These results are in agreement with the known role of 
HRI as a negative regulator of erythroblast size. In addition, they clearly show that EpoR signaling 
regulates cell size independently of the HRI pathway, since, even in the absence of HRI, EpoR 
signaling promotes larger erythroblasts (Fig 5b-d) and reticulocytes (Fig 5e).   
 
Several EpoR signaling pathways are implicated in the regulation of cell size 
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The EpoR activates three principal signaling pathways: ras/MAP kinase, Stat5, and phosphatidylinositol 
3-kinase (PI3K) 57,58. Neonatal mice hypomorphic for Stat5 have microcytic anemia 59. Here we found 
that, similarly, circulating red cells from E13.5 Stat5 -deficient embryos are smaller than wild-type 
littermates (Extended Data Fig 6a-b). Therefore, Stat5 signaling contributes to the regulation of cell 
size by EpoR. To determine whether other pathways are implicated, we examined the effects of U0126, 
a MEK1- and MEK2-specific inhibitor 60, and of LY 294002, a specific inhibitor of PI3K 61, on 
differentiating fetal liver cells. We found that PI3K inhibition significantly decreased the size of early 
(‘S2’) and late (‘S3) erythroblasts and reticulocytes. By contrast, inhibition of MEK1/2 had no significant 
effect on reticulocyte size, though it appeared to result in larger early erythroblasts (Extended Data Fig 
6c, d). Therefore, it is likely that cell size regulation by EpoR is the integrated result of multiple signaling 
pathways.  
 
Accelerated maturation in the absence of EpoR, assessed independently of cell size 
 
Cell size is frequently used as a convenient indicator of maturational stage during ETD (62-65). Our initial 
impression was that Bcl-xL- Epor-/- erythroblasts completed their maturation sooner than EpoR- Epor-/- 
erythroblasts (Fig 1e g). However, the finding that cell size is consistently smaller in Bcl-xL- Epor-/- 
erythroblasts at all maturational stages, including reticulocyte, made cell size an unreliable indicator of 
maturational stage differences between Bcl-xL- Epor-/- and EpoR- Epor-/- erythroblasts. We therefore 
assessed maturation using two alternative measures.  
 
First, we looked at the level of expression of Ter119, a cell surface marker that emerges with the onset 
of ETD and whose expression increases with maturation 62-65. We found that Ter119 levels increased 
more rapidly in Bcl-xL- Epor-/- erythroblasts, reaching significantly higher levels than in EpoR- Epor-/- 
erythroblasts at 48 h (Extended Data Fig 7a). Second, we looked at nuclear offset, a quantitative 
morphological measure of nuclear eccentricity that is independent of cell size and that was previously 
used to assess erythroblasts prior to enucleation 65 (Extended Data Fig 7b-d). Here we found that 
nuclear offset increases continuously throughout ETD. Early in ETD, when the nucleus is large, the 
geometrical centers (centroids) of the cell and the nucleus are close. With increasing maturation, the 
nucleus undergoes gradual condensation, and the distance between the cell and nuclear centroids, 
known as the ‘delta centroid’, gradually increases. The nuclear offset is the ratio of this distance to the 
cell diameter, making it independent of cell size (Extended Data Fig 7b). We found that nuclear offset 
increased earlier in Bcl-xL- Epor-/- erythroblasts, with the difference between Bcl-xL- Epor-/- and EpoR- 
Epor-/- erythroblasts peaking at 48 h (p=0.02) (Extended Data Fig 7c, d). Taken together, the timing of 
both Ter119 expression and nuclear offset suggest that EpoR signaling prolongs erythroblast 
maturation.  
 
Epo increases cell size and prolongs erythroid maturation over a wide concentration range  
 
We next asked whether the effect of EpoR signaling on cell size is sensitive to Epo concentration. We 
harvested wild-type fetal liver CFU-e (‘S0’ in Fig 6a 40) and plated them in the presence of a range of 
Epo concentrations. We followed their differentiation as they sequentially upregulate CD71 and Ter119 
40. By 48 h, the cultures contained a mixture of erythroblasts at various maturational stages (S1 to S3, 
Fig 6a) as well as reticulocytes. We found that cell size was increased in an Epo-concentration- 
dependent manner, with larger cells at every stage of differentiation, including reticulocytes (Fig 6b, 
Extended Data Fig 8a). The Epo concentration range affecting cell size, from 0.01 to 10 Units/ml, 
covers the entirety of the physiological and stress range that is found for Epo in vivo 66,67. In addition to 
increasing reticulocyte diameter, higher Epo concentration also increased reticulocyte size distribution, 
as shown by respective coefficients of variation of the diameters, making them more heterogeneous 
(Extended Data Fig 8b). 
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Epo also caused a dose-dependent lag in differentiation. As expected, at 48 hours of culture, higher 
Epo resulted in higher cell number at all stages of differentiation (Extended Data Fig 8c). However, the 
distribution of erythroblasts was increasingly skewed in favor of earlier differentiation subsets 
(Extended Data Fig 8d). Thus, at 0.01 U/ml of Epo, 5.4% of erythroblasts were in the earlier, S1 stage, 
and 62% had attained the more advanced, S3 stage; by contrast, at 10 U/ml, as many as 22% of 
erythroblasts were still in S1, and only 46% reached S3. Similarly, the intensity of Ter119 expression in 
erythroblasts pooled from all subsets (S1 to S3, Extended Data Fig 8e) decreased at higher Epo 
concentrations. 
 
We further assessed cell maturation by measuring the nuclear offset, which decreased with increasing 
Epo concentration at all flow-cytometric stages (Extended Data Fig 8e, f). Together these findings 
suggest that Epo prolongs ETD in a dose-dependent manner. These observations are consistent with 
our finding that Bcl-xL- Epor-/- erythroblasts, which lack EpoR signaling altogether, have a significantly 
faster differentiation rate (Fig 1e, Extended Data Fig 7).  
 
A skewed distribution in favor of early erythroblasts is also seen in vivo following Epo administration 
(e.g. Extended Data Figure 3a), consistent with prolongation of early ETD.  
 
Epo administration stimulates a dose-dependent increase in erythroblast cell size in vivo 
 
To assess whether Epo increases erythroblast cell size in vivo, we injected mice with a range of Epo 
doses, or with saline control. Erythroblast maturational stage is routinely assessed using erythroblast 
cell size 62,63 (e.g. Extended Data Figure 3a), but this approach precludes an assessment of cell size 
regulation. Therefore, to determine whether Epo increases erythroblast cell size at a given maturational 
stage, we used imaging flow cytometry to determine nuclear offset, a size-independent means of 
assessing maturational stage. Nuclear offset quantitates morphological maturation by measuring 
increasing nuclear eccentricity (Fig 6c). We divided the nuclear offset distribution of Ter119+ bone-
marrow erythroblasts from saline-injected mice into quintiles (Fig 6d). Quintiles with increasing nuclear 
offset corresponded to increasingly mature erythroblast subsets as judged by the established criteria of 
decreasing CD71 and cell area, confirming the utility of this approach (Fig 6e). We then used the 
nuclear offset quintile values from these control mice to classify Ter119+ erythroblasts from Epo -
injected mice into five maturational stages. We found that for a given nuclear-offset -defined 
maturational stage, cell diameter increased with increasing Epo dose. This effect was particularly 
striking in erythroblasts that corresponded to the two most mature quintiles (Fig 6f, g), clearly 
confirming that Epo dose regulates erythroblast cell size.   
 
Epo administration to healthy human volunteers increases red cell size (MCV) and size variation 
(RDW) for prolonged periods 
 
To determine whether EpoR regulates cell size in vivo in humans, we examined healthy volunteers in 
three intervention studies. Participants were either given Epo (studies #1 and #2, Fig 6h, Extended 
Data Fig 9,10), or subjected to phlebotomy (study #3, Fig 6h, Extended Data Fig 11). In studies #1 
and #2, the effect of Epo on athletic performance was examined, and will be either reported elsewhere 
(study #1) or was previously reported (study #2 68). Here we present the detailed blood parameters 
associated with these studies. 
 
In study #1 (Fig 6h, Extended Data Fig 9), subjects at sea level had baseline parameters established 
during four weekly blood samplings. They were then injected with either Epo (20 IU /kg every other day, 
25 subjects) or placebo (9 subjects) for 3 weeks. On average, hemoglobin levels increased by 5% over 
baseline values in the Epo group during the treatment period. Blood sampling continued for an 
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additional five weeks following cessation of treatment. In study #2 (Fig 6h, Extended Data Fig 10), 
baseline measurements were followed by weekly dosing with Epo (24 subjects) or placebo (24 
subjects) for 7 weeks. Epo dosing (5000 to 10000 IU) was adjusted for each subject, to achieve an 
increase of 10 to 15% in hemoglobin over baseline. Follow-up continued for a month after cessation of 
treatment. In study #3 (Fig 6h, Extended Data Fig 11), 21 subjects participated in a randomized 
double-blind placebo-controlled crossover study in which 900 ml of whole blood was withdrawn from 
the treatment group by venipuncture. Subjects were then followed for 25 days.  
 
In all three studies, there was a significant increase in MCV in the treatment groups compared with 
baseline values and with the placebo group, which persisted well beyond the treatment period 
(Extended Data Fig 9-11, Supplemental statistical analysis). There was no correlation between 
MCV and the reticulocyte count, whose time courses were clearly divergent (r < 0.1 between MCV and 
reticulocyte count in all three studies, Pearson’s product-moment correlation, Supplemental statistical 
analysis). In studies #1 and #2, the reticulocyte count increased during Epo treatment, but declined 
sharply below baseline values as soon as Epo treatment ceased. By contrast, MCV values remained 
high (Fig 6h). Similarly, in study #3, MCV values continued to climb at a time when the reticulocyte 
count was declining (Fig 6h). Thus, the increase in MCV is not the result of an increase in the number 
of reticulocytes. Together with the increase in MCV, there was an increase in red-cell distribution width 
(RDW-SD, Extended Data Fig 9,10; no RDW is available for study #3). There was a significant, 
positive correlation between MCV and RDW-SD (r = 0.51, p=2 x 10-28 for study #1; r = 0.52, 2 x 10-24 for 
study #2).  
 
Although the largest loss in red cell volume occurs during reticulocyte maturation, red cell size 
continues to decline as a function of red cell age 69-73. The MCV represents the average volume of all 
circulating cells; therefore, we considered the possibility that the persistently elevated MCV following 
Epo administration might be the result of the expected increase in the relative number of younger red 
cells, rather than an increase in their size. To address this, we simulated the expected increase in MCV 
that would arise only from an increase in the proportion of younger red cells, assuming no effect of 
EpoR signaling on red cell size (supplementary materials, ‘Simulation of MCV’). This simulation 
indicated that an increased proportion of younger red cells cannot fully account for the extent or 
duration of the observed increase in MCV following Epo administration, consistent with a direct role for 




Using a genetic model in which we provided Epor-/- fetal liver cells with exogenous survival signaling, 
we identified novel non-redundant functions for EpoR during ETD. We found that EpoR signaling 
determines the number of cell divisions, their speed, as well as the duration of terminal differentiation.  
While it has little effect on the broad ETD transcriptional program, it drives the formation of qualitatively 
different, larger red cells. Human intervention studies are consistent with a similar effect of EpoR 
signaling on red cell size in human erythropoiesis. In the discussion below we integrate these 
apparently disparate effects into a coherent model for EpoR signaling during terminal differentiation 
(Fig 7). We discuss previously unexplained instances of macrocytic and heterogeneously-sized red 
cells, now interpretable as the result of EpoR signaling during hypoxic stress. 
 
The ETD is a time of continuous and rapid change in many aspects of the cell, including transcriptional 
state, susceptibility to apoptosis, cell cycle dynamics, cell size and morphology. Our results strengthen 
a model in which these changes do not progress uniformly throughout ETD, but rather, are controlled 
differently in two principal phases: an early, Epo-dependent phase, and an Epo-independent late phase 
39 (Fig 7). EpoR expression peaks in early erythroblasts, which are exquisitely sensitive 74 and 
dependent on EpoR signaling for survival 8,62,75. By contrast, late erythroblasts downregulate EpoR 
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expression 13 and are relatively resistant to apoptosis 62,75. The functions we identified here for EpoR 
signaling in ETD are similarly focused on early erythroblasts.  
 
Our work documents five key effects of EpoR signaling in addition to its anti-apoptosis effects: 1) it 
prolongs the duration of ETD, as determined by delayed expression of cell surface markers and a 
delayed increase in nuclear offset, compared with cells lacking the EpoR; 2) it increases the number of 
cell cycles; 3) it skews the distribution of developing erythroblasts in favor of earlier erythroblasts; 4) it 
increases cell cycle speed; and 5) it increases cell size throughout ETD, generating red cells that are 
larger and more heterogeneous in size. The prolongation of ETD is consistent with the increase in the 
number of cycles. Neither informs us directly regarding the stage(s) of ETD that are being prolonged. 
However, the skewed distribution in favor of early erythroblasts indicates, based on the ergodic 
principle 76, that EpoR signaling prolongs early ETD relative to the late ETD phase. Together, these 
observations suggest that EpoR prolongs the early phase of ETD by increasing the number of early 
ETD cell cycles. This conclusion is consistent with our data, showing the largest differences in cell cycle 
number in the first 24 h of ETD; and with the known responsiveness of early ETD to EpoR signaling. In 
addition, it explains the observation that EpoR increases cell cycle speed, since early ETD cell cycles 
are unusually fast 27,28, and much faster than cycles in late ETD 27,28,77; our observations show that 
EpoR signaling regulates the speed of these unique cycles.   
 
Therefore, of the five effects of EpoR signaling that we document, the first four are outcomes of an 
EpoR-driven increase in the number and speed of early ETD cell cycles (Fig 7). An increase in the 
number of these cycles prolongs the early phase of ETD, accounting for the relative increase in the 
number of early erythroblasts and for the increased duration of ETD as a whole.  
 
One of the factors known to regulate the onset of late ETD is p27KIP1, whose induction promotes slower 
cycling and cell cycle exit 51,78,79. The expression of cell cycle regulators was largely unchanged in the 
absence of EpoR signaling, with the exception of p27KIP1, which was induced prematurely (Extended 
Data Fig 4). A second CDK inhibitor, p57KIP2, was also elevated (Extended Data Fig 4). Interestingly, 
premature p27KIP1 expression and morphological maturation were noted in primitive yolk-sac 
erythroblasts cultured in the absence of Epo 21. The converse was found in Klf1-/- erythroblasts, which 
fail to induce p27KIP1 and fail to undergo cell cycle exit; exogenous expression of p27KIP1 rescues mitotic 
exit in these cells 54, and also promotes terminal differentiation in K562 erythroleukemia cells 80. It is 
therefore likely that EpoR signaling extends the rapid cycling phase in early ETD, at least in part, by 
delaying the induction of p27KIP1. This is also consistent with a previous report showing that EpoR 
downregulates p27KIP1 53. As expression of EpoR decreases in the later stage of ETD, its function in 
maintaining the rate of cell cycle decreases while its anti-apoptotic function is assumed by increased 
Bcl-xL 81. 
 
The most surprising of our findings was the effect of EpoR signaling on cell size. We found that 
erythroblasts differentiating in the absence of EpoR gave rise to smaller red cells, in spite of undergoing 
fewer cell cycles. Further, cell size was sensitive to Epo concentration within the physiological and 
stress range 67. These findings appear contrary to the well-established link between the loss in cell size 
and the number of cell divisions. Thus, deletions of E2F4 29, cyclin D3 30, CDK2 or CDK4 31 each reduce 
the number of cell divisions during ETD and result in macrocytic red cells. Similarly, macrocytic red 
cells are seen when nucleotide pools limit DNA synthesis rate, as in patients treated with hydroxyurea 
32, or in B12 or folate deficiencies. We found that the EpoR effect on red cell size was also independent 
of a second established pathway, in which red cell size is regulated in response to iron status. Iron and 
heme deficiency activate HRI, which inhibits eIF2α and global protein translation, resulting in small, 
hypochromic red cells 34,56. Here we found that erythroblasts lacking the EpoR failed to upregulate the 
transferrin receptor (CD71), potentially leading to intracellular iron deficiency. However, iron 
supplementation did not rescue the smaller size of Epor-/- erythroblasts. Further, the cell size deficit 
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persisted in erythroblasts that were doubly deleted for both Epor and Hri. While this experiment does 
not exclude an interaction between HRI and EpoR signaling 35, it shows conclusively that EpoR 
signaling regulates red cell size independently of HRI.  
 
Our data therefore suggest that EpoR regulates red cell size through a novel mechanism. The finding 
that the EpoR-driven increase in cell size begins in early erythroblasts (Fig 6b, Extended Data Fig 8a) 
suggests that it takes place in the very same cells in which EpoR signaling also induces additional rapid 
cycles. We propose that the well-established coupling of cell size loss with cell divisions is a default 
state, seen in cells where EpoR signaling is weak or absent. We further suggest that strong EpoR 
signaling, as may occur in early erythroblasts 74, can override this default state and maintain cell size in 
spite of rapid cycling (Fig 7). The maintenance of cell size in dividing cell populations is the norm in 
most tissues 82,83 and so it is possible that EpoR signaling permits early erythroblasts to employ similar 
pathways of size control as those found outside ETD. The mechanisms that determine the 
characteristic size of a cell and that maintain it through cell divisions are not fully understood, but are 
thought to depend on strong growth factor signaling to promote the metabolic pathways required for 
building biomass 83. To maintain their size, cells must attain a size threshold before committing to cell 
division; in avian erythroblasts and other cell types, a larger size correlates with a longer G1 phase 82,84. 
The ability of EpoR signaling to increase cell size in early erythroblasts, which are some of the most 
rapidly dividing cells in vivo 27,28, predicts that these cells have exceptionally efficient mechanisms for 
growth. Conversely, this also implies that impairments in growth pathways would have a specifically 
deleterious effect in early erythroblasts, potentially contributing to the selective damage of 
ribosomopathies in the erythroid lineage 85.  
 
Together with an increase in cell size, high Epo levels also increased cell size heterogeneity, in both 
mouse (Extended Data Fig 8b) and human (RDW-SD, Fig 6d, Extended Data Fig 9, 10). Unlike low 
Epo levels, which generate only weak EpoR signals and therefore relatively uniform small cells, high 
levels of Epo might be expected to support the survival of erythroblasts with varying Epo sensitivities 
62,86, in which the strength of EpoR signaling may vary widely, giving rise to a range of red cell sizes 
(Fig 7).  
 
The relationship between high MCV, high RDW and high levels of Epo may have been overlooked 
previously by being attributed to an increase in reticulocytes. We have excluded this possibility, finding 
no correlation between reticulocyte numbers and MCV. High MCV persisted well after Epo and 
reticulocytes declined. We also found that the extent and duration of increase in MCV following Epo 
administration cannot be accounted for solely by the skewing in the age distribution of circulating red 
cells in favor of younger cells (see supplementary data, ‘simulation of MCV’). Indeed, our mouse data 
show increased cell size throughout terminal differentiation, generating larger than normal reticulocytes, 
and not simply more numerous reticulocytes. 
 
Recent GWAS and other studies have linked multiple genomic loci to the regulation of MCV 87-90. These 
include Epo, EpoR and lnk, all which might be expected to alter EpoR signaling strength 91. An Epo-
mediated increase in MCV in clinical settings might be tempered by iron status or by pathology affecting 
terminal differentiation. Indeed, Nevertheless, our work predicts that in the absence of erythroid 
pathology or nutritional deficiencies, Epo levels might be a key determinant of MCV. Indeed, an 
increase in Epo levels might account for the hitherto unexplained macrocytosis in hypoxemic patients 
with chronic obstructive pulmonary disease 92,93 and in iron-replete pregnancy 94,95. An increase in RDW 
was recently proposed as a potential longer-term biomarker for brief hypoxemic episodes in conditions 
such as acute respiratory distress, sepsis or congestive heart failure 96,97. The regulation of MCV by 
Epo levels also clarifies previously unexplained changes in red cell volume associated with Kit function. 
Kit regulates the proliferation of early erythroid progenitors but is downregulated with entry into ETD. 
Gain of function Kit mutations in mice lead to erythrocytosis as a result of excess progenitors entering 
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ETD; the red cells are microcytic 98, presumably in response to a compensatory decrease in Epo levels. 
Conversely, loss of function Kit mutations are associated with an increased MCV, which is in proportion 
to the severity of anemia 98,99, and can be explained by a paucity of progenitors entering ETD and the 
expected compensatory increase in Epo 100. Transgenic expression of Epo rescues the lethal c-KitW/W 
mutation, also resulting in macrocytic red cells 99. Given the persistence of higher MCV and RDW 
beyond the period in which Epo is elevated, these markers may be useful in detecting hypoxic stress in 
the clinic as well as Epo doping by athletes.  
 
The adaptive value, if any, of a higher MCV in erythropoietic stress is not yet clear. Surprisingly, the 
increase in MCV in our human intervention studies was not associated with increased corpuscular 
hemoglobin (MCH). On the contrary, we found a statistically significant decrease in mean corpuscular 
hemoglobin concentration (MCHC) in both Epo intervention studies (Extended Data Fig 9, 10), though 
not in the phlebotomy intervention (Extended Data Fig 11). It is of interest, however, that a lower 
MCHC enhances the action of 2, 3, diphosphoglycerate (2,3 DPG), an allosteric regulator that binds to 
hemoglobin and lowers its affinity for oxygen. The levels of 2,3 DPG in red cells increase in response to 
anemia or hypoxia, improving the unloading of oxygen in tissues 101,102. The affinity of 2,3 -DPG to 
hemoglobin increases significantly at lower MCHC 103. A lower MCHC may therefore improve the 2,3-
DPG -dependent unloading of oxygen in metabolically active tissues during erythropoietic stress. 
Indeed, a lower MCHC is also an HRI- regulated outcome characteristic of microcytic iron-deficiency 
anemia, possibly for similar reasons. The EpoR-regulated increase in MCV might therefore provide a 
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Figures and Figure legends: 
 
 
Figure 1 Abnormal ETD in the absence of EpoR signaling  
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a Experimental design. E12.5 Epor-/- fetal livers were transduced with bicistronic retroviral vectors 
encoding either Bcl-xL or EpoR, linked by an internal ribosomal entry site (IRES) to human CD4 (hCD4) 
or GFP reporters. Transduced cells differentiated in vitro into red cells over the ensuing 72 hours.   
b Epor-/- CFU-e colonies, scored 48 hours following transduction with either EpoR or Bcl-xL. Epo 
was added to the medium where indicated. Epor-/- fetal liver cells were also transduced with retroviral 
vectors encoding the following: ‘empty’ vector (‘V’), constitutively active Stat5 (Stat5 1*6), or doubly 
transduced with both Bcl-xL and Stat5 1*6. Data pooled from 3 independent experiments. Only CFU-e 
colonies of a size comparable to those of wild-type colonies were scored.  
c Representative colonies from an experiment as in ‘b’ 
d Colony area occupied by each of 75 colonies for each genotype (EpoR- Epor-/- or Bcl-xL- Epor-/-
). Data pooled from 3 independent experiments as in ‘b’.  
e Cytospin preparations of transduced Epor-/- fetal liver cells cultured in liquid medium for 36 
hours, in the presence or absence of Epo as indicated. Cells were stained for hemoglobin with 
diaminobenzidine (brown stain, arrowheads) and counter-stained with Giemsa. Representative of 4 
independent experiments. Double-headed arrows point at enucleated red cells; arrows point at 
pyrenocytes (extruded nuclei). The micrograph in the bottom panel is representative of cultures both in 
the presence or absence of Epo.  
f, g Flow cytometric CD71/Ter119 profiles of freshly harvested Epor-/- and wild-type littermate fetal 
livers (f), and of Epor-/- fetal liver cells 18 and 36 hours post transduction and culture in Epo-containing 
medium (g).  
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Figure 2 EpoR stimulates shorter cell cycle in early erythroblasts in vitro and in vivo 
a The EpoR is required for CD71 upregulation. Epor-/- fetal livers were transduced with either 
EpoR or Bcl-xL retroviral vectors carrying the hCD4 reporter (see Extended Data Fig 2b for 
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experimental design). Transduced erythroid cells (hCD4+Lin-) were examined for expression of CD71 
and Ter119.   
b Time course of CD71 expression following EpoR or Bcl-xL retroviral transduction as in ‘a’. MFI; 
median fluorescence intensity, expressed relative to t=0. Data from two independent experiments.  
c Growth of Epor-/- fetal liver transduced with either Bcl-xL or EpoR. Viable hCD4+Lin- cells were 
counted at the indicated times. Fe-SIH (10 μM) or deoxynucleosides (dN, 0.7 μM) were added to the 
medium as indicated. ‘Tfrc’ cells were doubly transduced with both Tfrc, and either Epor or Bcl-xL. Data 
are pooled for each set of conditions from n=4 independent experiments (‘control’ growth curves in 
which cells were transduced with either EpoR or Bcl-xL but without additional manipulation of iron or dN 
were included in every experiment). Data are expressed relative to cell number at t=0, and were fit with 
exponential curves (R2 values ranging between 0.8 and 0.94, least squares fit). 
d Cell viability, expressed as the fraction (%) of trypan blue negative cells, for the same set of 
experiments shown in ‘c’. 
e Cell doubling times ± 95% confidence intervals, calculated from the fitting of exponential growth 
curves to the data in ‘e’.  
f Cell cycle shortening in early erythroblasts in vivo. Mice transgenic for a fusion of histone H2B 
and a fluorescence-timer protein (H2B-FT) were injected with either saline or Epo (100 U) at 0 and 24 
h. Bone-marrow was analyzed at 48 h. H2B-FT fluoresces blue (‘B’) for 1-2 h immediately following 
synthesis, and matures into a long-lived red fluorescent protein (‘R’). The blue to red fluorescence ratio 
in the cell (expressed as B/(B+R)) is a function of cell cycle length 28. Shown are histograms of B/(B+R) 
in live EryA erythroblasts (Ter119highCD71highFSChigh). Histogram overlays are for 2 mice injected with 
saline and 2 mice injected with Epo. 
g Relative cell cycle lengths for the 4 mice analyzed in ‘f’, for each of the indicated erythroblast 
maturation stages: ProE (Ter119medCD71), EryA (Ter119highCD71highFSChigh), EryB 
(Ter119highCD71highFSClow), EryC (Ter119highCD71lowFSClow). p -value is for a paired t test, pairing the 
average values for Epo-injected and Saline injected mice for each of the early erythroblast stages 
(ProE and EryA/B). Cell cycle length was calculated as R/B.   
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Figure 3 EpoR regulates the speed of S phase 
a Cell cycle analysis of Epor-/- fetal liver cells transduced with either EpoR or Bcl-xL and cultured 
as in Fig 2b.  Cells were pulsed with BrdU for 30 min at t=9 h and were immediately harvested for 
analysis. The fraction (%) of erythroblasts (hCD4+Lin-) in S phase is indicated, as is S phase speed, 
measured as the intra-S phase rate of BrdU incorporation (BrdU MFI within the S phase gate).  
b Summary of cell cycle status and S phase speed, as measured by intra-S phase BrdU 
incorporation in EpoR or Bcl-xL-transduced Epor-/- fetal liver cells. Data is pooled from 6 independent 
experiments similar to ‘a’. In all cases, cells were pulsed with BrdU for 30 minutes prior to harvesting for 
analysis. Data are mean ± sem. Intra-S phase BrdU (MFI) is expressed as the ratio to BrdU MFI of Bcl-
xL-transduced fetal liver cells at t=0 in each experiment.  Significance p values are paired t test, pairing 
EpoR and Bcl-xL-transduced cells for each time point across all experiments (upper panel), and for t=9 
and t=19 h in all experiments (middle and lower panels). 
c Effect of the cell-permeable iron carrier, Fe-SIH (10 mM) on S phase speed.  Experiment and 
cell cycle analysis as in ‘b’.  Cells were harvested at t=9 h.  
d, e Summary of S phase speed (d) and cell cycle status (e) in EpoR and Bcl-xL –transduced Epor-/- 
fetal liver cells at t=9 h, experimental design as in Fig 2b, and ‘a’ to ‘c’ above. S phase speed is 
expressed relative to the speed at t=0 in each experiment. Shown are the effects of adding Fe-SIH or 
dN to the medium, or of doubly transducing cells with both Bcl-xL and Tfrc. Data are mean ± sem for n = 
4 independent experiments each for Fe-SIH and dN, and n = 3  for Tfrc. All experiments also had Epor-
/- fetal liver cells transduced with EpoR and with Bcl-xL without additional additives or transductions. 
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a Cell and nuclear diameter of hCD4+Lin- erythroblasts, measured by imaging flow cytometry.  
Experiment as in Fig 2b. Polystyrene beads of known diameters were used for calibration (see 
methods, Extended Data Figure 4a).  Datapoints are population medians for individual samples, with 
50,000 cells imaged per sample. Box and whiskers mark the 25th to 75th percentiles and min to max 
values, respectively, with the median indicated. Data pooled from 7 independent experiments, p -values 
are from 2-tailed paired t-tests, pairing EpoR and Bcl-xL -transduced cells in each experiment.  
b A representative experiment as in ‘a’, showing individual sample contour plots overlaid on 
scatter plots (each dot is one cell), of nuclear diameter vs. cell diameter. The effect of adding Fe-SIH to 
the culture medium is also shown. Data are hCD4+Lin- erythroblasts at 48h post transduction,  
c Distinguishing erythroblasts from reticulocytes using imaging flow cytometry, with the nuclear 
dye Draq5. The analysis was performed on Ter119+ cells. Representative images are shown, from 
cultures of Epor-/- fetal liver cells that were doubly transduced with bicistronic retroviral vectors encoding 
GFP and hCD4 reporters (see Extended Data Fig 1a), at 48 hours post transduction. 
d Reticulocyte cell diameter in cultures of EpoR -Epor-/- or Bcl-xL- Epor-/- at 48 h post transduction, 
identified as in ‘c’. Data are population medians from 5 independent experiments. Box and whiskers as 
in ‘a’.  
e Reticulocyte diameters in cultures of Epor-/- fetal liver cells that were doubly- transduced with 
bicistronic vectors carrying GFP and hCD4 reporters (Extended Data Fig 1a). These vectors were 
either ‘empty’ (VGFP, VhCD4) or encoded either Bcl-xL or EpoR (Bcl-xLGFP, EpoRhCD4). Violin lines mark the 
25th, 50th and 75th percentile with a white circle marking the mean. Representative of two independent 
experiments. 
  
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted December 1, 2020. ; https://doi.org/10.1101/2020.11.30.404780doi: bioRxiv preprint 
 
 
Figure 5 EpoR regulates cell size independently of HRI  
a Epor-/- and doubly -deleted Epor-/-Hri-/- E12.5 embryos with wild-type littermates   
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b Cell and nuclear diameters in fetal livers from either Epor-/- or Epor-/-Hri-/- embryos, transduced 
with either EpoR or Bcl-xL, at t=48h post transduction. Individual sample contour plots are overlaid on 
scatter plots (each dot is one cell).   
c Summary data for cell and nuclear area, for two independent experiments as in ‘b’, each 
containing all 4 genotype/retrovirus combinations. Data are mean ± SD for each cell population. Each 
transduced population consisted of pooled fetal liver cells from either Epor-/- or  Epor-/-Hri-/- embryos.  
d Imaging flow cytometry of representative Lin-hCD4+Ter119+ erythroblasts from each of the 
genotype/retroviral combinations at t= 48 h.  
e Epor-/- and Epor-/-Hri-/- Reticulocyte cell diameter, from cultures transduced with either EpoR or 
Bcl-xL. Representative of 2 experiments. Violin lines mark the 25th, 50th and 75th percentile with a white 
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Figure 6 Red cell size is sensitive to Epo concentration in both mice and humans 
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a, b Epo concentration effect on ETD. Wild-type fetal liver cells were enriched for CFU-e progenitors 
(‘S0’) and differentiated in vitro, in a range of Epo concentrations between 0.01 and 20 U/ ml. Cultures 
were analyzed at 48 h. Data is representative of two independent experiments. 
a  S0 cells upregulate cell surface markers CD71 and Ter119 during differentiation. At 48h cells 
are distributed between erythroblast subsets S1, S2 and S3. The shown example is from a culture in 
the presence of Epo at 0.1 U/ml.  
b  Cell diameter distributions of S0 cells at t= 0h, and of erythroblast subsets S1 to S3 at 48 h, for 
cultures in the presence of the indicated Epo concentrations. Violin lines mark the 25th, 50th and 75th 
percentile with a white circle marking the mean.  
c  Nuclear offset is the ratio of the delta centroid (distance between the centers of the cell and the 
nucleus, D) and the cell diameter. It is a measure of nuclear eccentricity that is independent of cell size. 
The cartoon indicates how nuclear offset can be used to measure the increasing nuclear eccentricity 
during erythroid morphological maturation.    
d-g Mice were injected with either saline (n = 2) or Epo (5 U, 20 U or 100 U, n=2 for each Epo 
dose), and bone marrow was analyzed at 48 h.  
d Ter119+ bone marrow erythroblasts in saline-injected mice were divided into 5 maturational 
stages, by dividing the nuclear offset distribution into quintiles.  
e CD71/ forward -scatter (FSC) histograms for Ter119+ erythroblasts in each of the nuclear offset 
quintiles. For mice injected with Epo, cells were divided into 5 maturational stages based on the nuclear 
offset values defined by the control (saline) nuclear offset quintiles.  
f Cell diameter for each of the nuclear offset quintiles in ‘d, e’, for each injected Epo dose. Violin 
lines mark the 25th, 50th and 75th percentile with a white circle marking the mean. Data are 
representative from one of two mice injected for each Epo dose.   
g Median cell diameter and median nuclear offset values for cells in each nuclear offset quintile, 
for mice injected with either Epo (100 U) or Saline. Each data point is for one mouse.  
h MCV and reticulocyte count in three independent human intervention studies.  In studies #1 & 
#2, Epo was administered during the period indicated. In study #3, participants were subjected to 
phlebotomy at the time indicated (see text and methods for details). Because of individual variability 
between participants in many of the hematological parameters, data is represented as fractional 
change relative to the baseline values of each participant. All hematological parameters and statistical 
significance values as well as results for placebo control groups are in Extended Data Figures 8-10 
and Supplementary statistical analysis. MCV, mean corpuscular volume; Retics, reticulocyte count.  
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Figure 7 EpoR signaling promotes rapid cycling while maintaining cell size in early 
erythroblasts 
Proposed model explaining EpoR-dependent functions during ETD. Only early erythroblasts express 
appreciable cell surface EpoR and are sensitive to EpoR signaling. When EpoR signaling is weak or 
absent, as in late erythroblasts, or in early erythroblasts in the presence of low Epo, cell divisions lead 
to a loss in cell size.  In contrast, strong EpoR signaling, as seen in Epo-sensitive early erythroblasts, 
can override this default state and simultaneously increase rapid cycling while maintaining cell size. As 
consequence, high Epo levels increase the duration of the early ETD phase, increase the relative 
frequency of early erythroblasts, and result in larger erythroblasts at every maturation stage, giving rise 
to larger red cells. In high Epo, red cell size is also more heterogeneous, a result of the varying 
sensitivities of early erythroblasts to Epo. Erythroblasts with low sensitivity to Epo, here represented as 
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cells expressing low levels of EpoR, are expected to attain only weak EpoR signaling even in the 
presence of high Epo, giving rise to smaller red cells.  
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